Immunomedics (IMMU) Announces Improved Efficacy of Veltuzumab and Pretargeted Anti-CD20 Combo in Lymphoma Model
More News related to IMMU
- Immunomedics Announces First Quarter Fiscal 2010 Results and Clinical Program Developments
- Immunomedics to Present at Upcoming Conferences
- Immunomedics Receives Corporate Award From New Jersey Inventors Hall of Fame
- Immunomedics (IMMU) Awarded 2 Small Business Grants from NIH
- Immunomedics Awarded Three Grants by NIH to Develop New Agents for Imaging and Therapy of Cancer
More News related to Corporate News
- Wright Medical Group (WMGI) Announces FDA Approval For CONSERVE Plus Total Hip Resurfacing System
- Vascular Solutions (VASC) Receives 501(k) Clearance from U.S. FDA for GuideLiner Catheter
- Glaxo (GSK) and XenoPort (XNPT) Announed that U.S. FDA Has Extended the Review Date of GSK1838262/XP13512
- Compugen (CGEN) Announces Discovery of Biomarker CGEN-40001 for Type 2 Diabetes
Immunomedics, Inc. (Nasdaq: IMMU) today announced that naked veltuzumab enhances the therapeutic response to a veltuzumab-based pretargeted radioimmunotherapy in a human non-Hodgkin's lymphoma model.
RAIT utilizes an antibody to deliver targeted radiation to tumors. One of the challenges of conventional RAIT is that antibodies that are not attached to their targets stay in the body for a significant period of time, exposing the body and the bone marrow, in particular, to the harmful effects of radiation unnecessarily, and limiting the level of the tolerated radioisotope dose.
Related Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
